Advertisement

Determination of Fc-Mediated Antibody-Effector Functions by Chromium Release Assay

  • Tina OtzEmail author
Protocol
  • 3.3k Downloads
Part of the Springer Protocols Handbooks book series (SPH)

Monoclonal antibodies (mAbs) can exert their biological functions by a large variety of mechanisms and have therefore become a major part in the treatment of diseases like viral infections and cancer. For the clinical efficacy of many mAbs Fc-mediated effector functions like antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) play an essential role. This protocol describes a simple method to test whether a monoclonal antibody is able to induce ADCC or CDC using a chromium release assay.

Keywords

Natural Killer Cell Target Cell Effector Cell Buffy Coat Antigen Density 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bhakdi S, Tranum-Jensen J (1991) Complement lysis: a hole is a hole. Immunol Today 9:318–320CrossRefGoogle Scholar
  2. Brunner KT, Mauel J, Cerottini JC, Chapuis B (1968) Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 2:181–196Google Scholar
  3. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 3:754–758CrossRefGoogle Scholar
  4. Clark MR (1997) IgG effector mechanisms. Chem Immunol 65:88–110PubMedCrossRefGoogle Scholar
  5. Clynes R (2006) Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 3:585–612CrossRefGoogle Scholar
  6. Clynes R, Ravetch JV (1995) Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 1:21–26CrossRefGoogle Scholar
  7. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 4:443–446Google Scholar
  8. Cooper NR (1985) The classical complement pathway: activation and regulation of the first complement component. Adv Immunol 37:151–216PubMedCrossRefGoogle Scholar
  9. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 13:4664–4669CrossRefGoogle Scholar
  10. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov 11:503–510 TodayGoogle Scholar
  11. Goldsby RA, Kindt TJ, Osborne BA, Kuby J (2003) Immunology, Fifth Edition, WH Freeman and Company, New York, 1–551Google Scholar
  12. Greenwood J, Clark M, Waldmann H (1993) Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 5:1098–1104CrossRefGoogle Scholar
  13. Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 4:487–499CrossRefGoogle Scholar
  14. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 5787:670–673CrossRefGoogle Scholar
  15. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 11:4005–4010CrossRefGoogle Scholar
  16. Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS (1995) The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 2:319–324Google Scholar
  17. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 5753:1510–1512CrossRefGoogle Scholar
  18. Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 1:19–28CrossRefGoogle Scholar
  19. Otz (2008) New approaches for an antibody-based treatment of CD20+ lymphoid neoplasia. tobias-lib.ub.uni-tuebingen.de/volltexte/2008/3316/index.html
  20. Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 5–6:640–656CrossRefGoogle Scholar
  21. Presta LG, Shields RL, Namenuk AK, Hong K, Meng YG (2002) Engineering therapeutic antibodies for improved function. Biochem Soc Trans 4:487–490Google Scholar
  22. Raju TS (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 4:471–478CrossRefGoogle Scholar
  23. Sanz L, Blanco B, Alvarez-Vallina L (2004) Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol 2:85–91CrossRefGoogle Scholar
  24. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 9:6591–6604CrossRefGoogle Scholar
  25. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 30:26733–26740CrossRefGoogle Scholar
  26. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 5:3466–3473Google Scholar
  27. Strome SE, Sausville EA, Mann D (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 9:1084–1095CrossRefGoogle Scholar
  28. Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 3:269–277CrossRefGoogle Scholar
  29. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940–3947PubMedCrossRefGoogle Scholar
  30. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 23:4717–4724CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.University of StuttgartInstitute for Cell Biology and ImmunologyStuttgartGermany

Personalised recommendations